The Randomized Etanercept Worldwide Evaluation (RENEWAL) trial combined the results of two trials performed in early 2000s testing efficacy and safety of etanercept, a blocking fusion protein anti-TNF-α, currently employed in the treatment of RA, in patients with chronic heart failure. Here, TNF is linked to congestive heart failure.